聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 1 小时 2 分钟 前

Atara Biotherapeutics Strengthens Board and Senior Management Team

周二, 04/08/2014 - 13:40
Matthew K. Fust joins Board of Directors Mitchall G. Clark named Chief Regulatory and Quality Assurance Officer BRISBANE & THOUSAND OAKS, Calif.--(Healthcare Sales & Marketing Network)--Atara Biotherapeutics, Inc., a drug development company with a ...
Biopharmaceuticals, Personnel
Atara Biotherapeutics, TGF-beta, myostatin, activin

JenaValve Expands Series C Venture Financing Round

周二, 04/08/2014 - 13:31
Valiance and RMM Join Second Closing Bringing Total Round to $72.5 Million; New Board Member Appointed WILMINGTON, Del. & MUNICH--(Healthcare Sales & Marketing Network)--JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacture...
Devices, Interventional Cardiology, Venture Capital
JenaValve Technology, TAVI, transcatheter, JenaClip, aortic valve

Takeda Responds to Verdict in Diabetes Drug Case

周二, 04/08/2014 - 13:22
DEERFIELD, Ill., April 8, 2014 -- (Healthcare Sales & Marketing Network) -- Takeda Pharmaceuticals U.S.A., Inc. announced that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 the jury found in ...
Biopharmaceuticals, Endocrinology, Litigation
Takeda Pharmaceuticals, Eli Lilly, ACTOS , pioglitazone, diabetes

Alios BioPharma Raises $41 Million in Series B Financing

周一, 04/07/2014 - 18:13
New Capital Will Fund Further Development of Respiratory Virus Therapies SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for respiratory viral diseases,...
Biopharmaceuticals, Venture Capital
Alios BioPharma

New Clinical Study Shows Masimo PVI(R) Helps Clinicians Optimize Fluid Administration in Patients Under Combined General and Epidural Anesthesia

周一, 04/07/2014 - 18:08
IRVINE, CA--(Healthcare Sales & Marketing Network) - Masimo (NASDAQ: MASI) announced today a recent study in the Journal of Monitoring and Computing demonstrates that Masimo's noninvasive PVI® parameter can help clinicians optimize fluid management and...
Devices, Monitoring
Masimo, PVI parameter, Masimo SET, rainbow sensor

Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company

周一, 04/07/2014 - 13:18
Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own Combined Company Expected to Have Significantly Increased Scale, Revenues, Profitability and Cash Flow to Deliver Sustainable Gro...
Biopharmaceuticals, Mergers & Acquisitions
Mallinckrodt, Questcor Pharmaceuticals

EndoBarrier(R) Therapy Receives Reimbursement Coverage in Israel

周一, 04/07/2014 - 13:09
LEXINGTON, Mass. & SYDNEY, Australia--(Healthcare Sales & Marketing Network)--GI Dynamics, Inc. (GID.AX) today announced that Clalit Health Services, Israel’s largest and one of the world’s largest health maintenance organization (HMO), has established a r...
Devices, Reimbursement
GI Dynamics, EndoBarrier Therapy

Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer

周一, 04/07/2014 - 13:04
Company to Accelerate Kinase Inhibitor Clinical Candidates in Cancer Company to Open Corporate Offices in Boston Area LAWRENCE, Kan.--(Healthcare Sales & Marketing Network)--Deciphera Pharmaceuticals, a clinical stage biotechnology company developing...
Biopharmaceuticals, Personnel
Deciphera Pharmaceuticals

Meda and Valeant Terminates Joint Ventures

周一, 04/07/2014 - 12:57
GÖTEBORG, Sweden--(Healthcare Sales & Marketing Network)--Meda (STO:MEDAA) has reached an agreement with Valeant to terminate the companies’ joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda ...
Biopharmaceuticals
Meda AB, Valeant, Flupirtine, Onsolis, Sublinox

Merck Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

周一, 04/07/2014 - 12:52
First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries Related Stories START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who ha...
Biopharmaceuticals, Oncology
Merck Serono, START2, L-BLP25, NSCLC

Genzyme to Resubmit Lemtrada(TM) Application for FDA Review

周一, 04/07/2014 - 12:42
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to resubmit in the s...
Biopharmaceuticals, Neurology
Genzyme, Sanofi, Lemtrada, alemtuzumab, multiple sclerosis

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong